Explore Business Standard
<b>Alembic in licensing deal with UCB</b><br><br> Alembic has entered into a licensing agreement with Belgium-based UCB for its drug delivery platform for anti-epileptic drug Keppra XR (Levetiracetam extended release tablets).<br><br> According to an official release issued by Alembic to the BSE today, under the terms of the agreement, it would receive milestone payments of $11 million and royalty on future worldwide net sales of Keppra XR.
<b>Alembic in licensing deal with UCB</b><br><br> Alembic has entered into a licensing agreement with Belgium-based UCB for its drug delivery platform for anti-epileptic drug Keppra XR (Levetiracetam extended release tablets).<br><br> According to an official release issued by Alembic to the BSE today, under the terms of the agreement, it would receive milestone payments of $11 million and royalty on future worldwide net sales of Keppra XR.